Engineering active lysostaphin variants that incorporate noncanonical amino acids and characterizing the effects of site‐specific PEGylation.

MLA

Batugal, Troy, et al. “Engineering Active Lysostaphin Variants That Incorporate Noncanonical Amino Acids and Characterizing the Effects of Site‐specific PEGylation.” Biotechnology & Bioengineering, vol. 120, no. 6, June 2023, pp. 1694–701. EBSCOhost, https://doi.org/10.1002/bit.28360.

APA

Batugal, T., Pendyala, G., Tomasovic, L., Varner, C., Caplin, J. D., Page, A. M., Davis, M., Satola, S. W., García, A. J., & Kane, R. S. (2023). Engineering active lysostaphin variants that incorporate noncanonical amino acids and characterizing the effects of site‐specific PEGylation. Biotechnology & Bioengineering, 120(6), 1694–1701. https://doi.org/10.1002/bit.28360

Chicago

Batugal, Troy, Geetanjali Pendyala, Luke Tomasovic, Chad Varner, Jeremy D. Caplin, Alexander M. Page, Michelle Davis, Sarah W. Satola, Andrés J. García, and Ravi S. Kane. 2023. “Engineering Active Lysostaphin Variants That Incorporate Noncanonical Amino Acids and Characterizing the Effects of Site‐specific PEGylation.” Biotechnology & Bioengineering 120 (6): 1694–1701. doi:10.1002/bit.28360.